Rejeunesse

Product Overview

Rejeunesse is a South Korean cross-linked hyaluronic acid (HA) dermal filler range manufactured by New Medic Co., Ltd. The facial filler portfolio includes Rejeunesse Fine, Deep, Shape, and the historically documented Contour formulation. All four contain 24 mg/mL cross-linked hyaluronic acid and 0.3% lidocaine hydrochloride (3 mg/mL). Developed using UPHEC™ purification and cross-linking technology, the range offers different gel characteristics for temporary facial wrinkle correction, soft-tissue volume restoration, and facial contouring.

Rejeunesse is formulated using non-animal-derived hyaluronic acid and supplied as a sterile, transparent, viscoelastic gel in pre-filled syringes.

The facial filler range is differentiated by its intended correction characteristics. Fine is positioned for subtle facial lines, Deep for more pronounced wrinkles and folds, Shape for structural facial contouring, and Contour for volume-oriented facial augmentation.

Rejeunesse Fine, Deep, and Shape are documented in the current JDBIO distribution portfolio. Contour appears in earlier manufacturer-associated catalogues, and its current commercial availability should be verified before procurement.

This product page focuses exclusively on the Rejeunesse HA facial filler range. Rejeunesse Sparkle, a separate skin rejuvenation formulation containing 20 mg/mL HA, is not included.

Key Features

• 24 mg/mL Cross-Linked Hyaluronic Acid: All four facial filler formulations contain stabilized, non-animal-derived HA designed for temporary physical soft-tissue restoration.
• 0.3% Lidocaine: Contains 3 mg/mL lidocaine hydrochloride, an amide-type local anesthetic included to help reduce discomfort associated with professional administration.
• Four Facial Filler Grades: Fine, Deep, Shape, and Contour provide different gel characteristics for a range of facial correction and contouring requirements.
• UPHEC™ Technology: Uses a manufacturer-described HA processing and purification approach intended to support gel quality and reduce residual manufacturing-related substances.
• 1.1 mL Pre-Filled Syringes: The documented facial filler presentations contain one 1.1 mL syringe per box, with needle specifications varying by formulation.

Composition & Specifications

The principal ingredient in Rejeunesse facial fillers is cross-linked hyaluronic acid at a concentration of 24 mg/mL.

The documented facial filler formulations additionally contain 0.3% lidocaine hydrochloride, equivalent to 3 mg/mL.

Although the four products share the same declared ingredient concentrations, they are differentiated by their gel characteristics and intended aesthetic applications.

Cross-Linked Hyaluronic Acid — 24 mg/mL

Hyaluronic acid is a naturally occurring glycosaminoglycan found in the extracellular matrix of connective tissues, including the skin.

Its hydrophilic molecular structure allows it to interact strongly with water, contributing to tissue hydration and viscoelasticity.

Rejeunesse facial fillers contain 24 mg/mL cross-linked hyaluronic acid, corresponding to a nominal 26.4 mg of HA in each 1.1 mL syringe.

Cross-linking introduces chemical connections between HA polymer chains, creating a stabilized gel network with greater resistance to degradation than non-crosslinked HA.

This stabilized structure provides the physical basis for temporary wrinkle correction, soft-tissue volume restoration, and facial contour enhancement.

Although Fine, Deep, Shape, and Contour share the same HA concentration, their different gel characteristics influence their intended correction properties.

Identical hyaluronic acid concentrations do not establish identical elasticity, cohesivity, lifting capacity, or clinical duration across different filler grades.

Lidocaine Hydrochloride — 0.3%

Lidocaine is an amide-type local anesthetic commonly incorporated into injectable dermal fillers.

It temporarily inhibits sensory nerve conduction by blocking voltage-gated sodium channels in nerve cell membranes.

This mechanism reduces the propagation of electrical impulses associated with pain.

Rejeunesse Fine, Deep, Shape, and Contour are documented with 0.3% lidocaine hydrochloride, equivalent to 3 mg/mL.

Lidocaine is included to help reduce discomfort associated with professional filler administration.

Its presence does not eliminate procedural discomfort or the potential complications associated with injectable HA fillers.

BDDE Cross-Linking

BDDE, or 1,4-butanediol diglycidyl ether, is a cross-linking agent used in manufacturing certain stabilized hyaluronic acid fillers.

During production, BDDE forms chemical connections between HA polymer chains, contributing to the mechanical characteristics of the finished gel.

Rejeunesse product materials describe purification processes intended to reduce residual BDDE.

The manufacturer's commercial documentation reports no detectable residual BDDE under its referenced testing conditions.

However, a nondetect result does not independently establish the complete absence of all cross-linking-related residues or eliminate the possibility of adverse reactions.

How Rejeunesse Hyaluronic Acid Fillers Work

Rejeunesse fillers provide temporary soft-tissue correction through the physical properties of cross-linked hyaluronic acid.

The stabilized HA gel occupies space within soft tissue and interacts with water, contributing to temporary volume restoration and wrinkle correction.

Physical Soft-Tissue Restoration

Cross-linked HA creates a hydrated gel structure capable of providing temporary physical support within soft tissue.

Different gel characteristics allow the Rejeunesse range to address various degrees of facial wrinkles, folds, and contour deficits.

Viscoelastic Gel Characteristics

Viscoelasticity describes how a material responds to mechanical forces through a combination of elastic and viscous behavior.

Elasticity contributes to resistance against deformation, while viscosity describes resistance to flow.

Rejeunesse Fine, Deep, Shape, and Contour are differentiated by their intended gel characteristics, progressing from relatively subtle wrinkle correction toward more pronounced structural volume support.

Temporary Biodegradation

Hyaluronic acid is biodegradable and gradually undergoes enzymatic and non-enzymatic breakdown.

Chemical cross-linking generally increases the resistance of HA gels to degradation.

The resulting aesthetic effects are temporary, with persistence influenced by the specific product, treatment conditions, and individual biological factors.

These mechanisms describe established properties of hyaluronic acid. They do not guarantee a particular clinical outcome or identical treatment duration across all Rejeunesse formulations.

Available Rejeunesse Facial Filler Variants

The Rejeunesse HA facial filler family includes Fine, Deep, Shape, and the historically documented Contour formulation.

All four contain 24 mg/mL cross-linked HA and 0.3% lidocaine. Their principal differences are gel characteristics, intended aesthetic correction, and documented needle specifications.

Rejeunesse Fine

Rejeunesse Fine is the formulation positioned for relatively subtle facial wrinkle correction.

It contains 24 mg/mL cross-linked hyaluronic acid and 0.3% lidocaine hydrochloride.

Fine is commercially associated with superficial facial wrinkles, fine lines, and selected smaller soft-tissue depressions.

Compared with the more volume-oriented Rejeunesse formulations, Fine is designed with gel characteristics suited to relatively delicate correction requirements.

Its documented presentation contains one 1.1 mL pre-filled syringe and two 30G needles.

Rejeunesse Deep

Rejeunesse Deep is the intermediate facial filler formulation.

It contains 24 mg/mL cross-linked hyaluronic acid and 0.3% lidocaine hydrochloride.

Deep is commercially positioned for temporary correction of moderate to deep facial wrinkles and folds.

Manufacturer-associated materials identify nasolabial folds and selected facial volume concerns among its intended aesthetic applications.

Compared with Fine, Deep is intended to provide relatively greater structural support.

Its documented package includes one 1.1 mL pre-filled syringe and two 27G needles.

Rejeunesse Shape

Rejeunesse Shape is the established volume-oriented facial filler within the current Rejeunesse distribution portfolio.

It contains 24 mg/mL cross-linked hyaluronic acid and 0.3% lidocaine hydrochloride.

Shape is commercially positioned for facial contour enhancement and temporary correction of more pronounced soft-tissue volume deficits.

The manufacturer's product materials associate Shape with facial contouring and selected cheek and chin augmentation applications.

The formulation is differentiated from Fine and Deep by its more structurally supportive gel characteristics.

Its documented presentation contains one 1.1 mL pre-filled syringe and two 26G needles.

Rejeunesse Contour

Rejeunesse Contour is a facial filler formulation documented in earlier Rejeunesse product catalogues.

It contains 24 mg/mL cross-linked hyaluronic acid and 0.3% lidocaine hydrochloride.

Contour is commercially positioned for more pronounced facial contour and volume correction.

Historical product materials associate the formulation with facial contouring applications involving the chin and other structural facial regions.

Its documented presentation contains one 1.1 mL pre-filled syringe, with a 23G needle specification.

Unlike Fine, Deep, and Shape, Contour is not included in JDBIO's newer published Rejeunesse product selection.

Consequently, its current manufacturing status, commercial availability, and destination-market authorization should be confirmed before procurement.

Rejeunesse Fine, Deep, and Shape are documented in current distribution materials. Contour is included for completeness based on historical product documentation. All four are lidocaine-containing formulations; non-lidocaine counterparts have not been independently verified for this facial filler range.

UPHEC™ Technology & Gel Quality

Rejeunesse product materials identify UPHEC™ as a proprietary manufacturing and purification technology associated with its cross-linked hyaluronic acid fillers.

Non-Animal-Derived Hyaluronic Acid

Rejeunesse is manufactured using hyaluronic acid obtained from non-animal sources.

Non-animal-derived HA is widely used in modern dermal filler manufacturing because it allows controlled production of a material chemically related to naturally occurring human hyaluronic acid.

However, non-animal origin does not eliminate the possibility of hypersensitivity, inflammation, or other adverse reactions.

Controlled Cross-Linking

Rejeunesse uses BDDE to stabilize its hyaluronic acid gel.

The resulting cross-linked polymer network contributes to the material's viscoelastic characteristics and resistance to degradation.

Different filler grades are developed with distinct physical characteristics despite sharing the same HA concentration.

Purification and Endotoxin Control

Rejeunesse technical materials emphasize purification and control of manufacturing-related residues.

The manufacturer's commercial documentation reports an endotoxin specification below 1.2 EU/mL and no detectable residual BDDE under its referenced testing conditions.

These values describe manufacturer-reported analytical characteristics and should not be interpreted as proof that the product is free from all adverse reactions.

Gel Uniformity and Extrusion

Rejeunesse is commercially described as a homogeneous HA gel designed to provide consistent extrusion characteristics.

Extrusion force refers to the mechanical force required to move a filler through a syringe and needle under specified conditions.

The manufacturer associates its formulation technology with smooth handling characteristics.

Such properties do not establish painless administration or independently demonstrate superiority over another HA filler.

Packaging & Product Presentation

Rejeunesse facial fillers are supplied as sterile hyaluronic acid gels in pre-filled syringes.

The documented Fine, Deep, Shape, and Contour presentations each contain one 1.1 mL syringe per box.

All four documented facial filler formulations contain 24 mg/mL cross-linked HA and 0.3% lidocaine.

Needle specifications are provided for packaging identification only and do not constitute instructions for injection technique or anatomical placement.

Buyers should verify the original product name, syringe volume, needle configuration, batch number, expiration date, and responsible manufacturer before procurement.

The 1.1 mL specification represents the nominal contents of the pre-filled syringe, not a recommended administration quantity. Packaging and accessories may vary by product generation or destination market.

Storage & Handling

Rejeunesse product documentation specifies storage between 2°C and 25°C.

The manufacturer-associated catalogue also identifies a shelf life of 24 months for the documented facial filler formulations.

• Storage Temperature: Store between 2°C and 25°C according to the documented product specifications.
• Freezing Protection: Do not freeze.
• Light Protection: Protect the product from direct sunlight.
• Original Packaging: Maintain the syringe in its original manufacturer packaging until required for authorized professional use.
• Sterile Barrier Integrity: Do not use products with damaged packaging or evidence of compromised sterility.
• Single-Use Handling: Follow the manufacturer's single-patient-use and disposal requirements.

The documented 24-month shelf life applies to the manufacturer-associated catalogue specifications. The exact expiration date and current validated storage conditions should be confirmed from the supplied product's original labeling.

Storage instructions may vary between product generations and regulatory markets. Follow the original manufacturer-issued instructions for use for the exact supplied formulation.

Safety & Regulatory Considerations

Rejeunesse facial fillers are injectable medical devices intended for use by appropriately qualified healthcare professionals.

Potential Adverse Reactions

Adverse reactions associated with injectable HA fillers may include localized pain, redness, swelling, bruising, tenderness, and itching.

Other complications can include infection, hypersensitivity reactions, delayed inflammation, persistent nodules, granulomatous reactions, and product migration.

Vascular Complications

Accidental intravascular introduction of dermal filler can obstruct blood flow and cause serious tissue injury.

Potential complications include vascular occlusion, tissue ischemia, necrosis, visual impairment, blindness, and stroke.

Certain facial areas have particularly important vascular safety considerations. Commercial references to facial contouring or augmentation do not independently establish an approved or safe application in every anatomical region.

Lidocaine-Related Precautions

All four documented Rejeunesse facial filler formulations contain 0.3% lidocaine hydrochloride.

Individuals with known hypersensitivity to lidocaine, other amide-type local anesthetics, or relevant formulation components may have contraindications to use.

The presence of lidocaine does not eliminate filler-related complications or guarantee an absence of procedural discomfort.

Hyaluronic Acid Biodegradation

Hyaluronic acid is biodegradable, and hyaluronidase may be used under appropriate medical circumstances to degrade HA fillers.

However, this does not guarantee complete reversal of every complication or prevention of permanent injury.

Manufacturer-Reported Duration

Historical Rejeunesse product materials describe expected aesthetic effects of approximately 8–12 months for Fine, 12–18 months for Deep and Shape, and 16–20 months for Contour.

These figures are manufacturer-reported estimates rather than guaranteed clinical durations.

Individual outcomes depend on the formulation, tissue characteristics, treatment conditions, and other physiological factors.

Regulatory Authorization

Rejeunesse is a South Korean HA dermal filler range manufactured by New Medic and distributed internationally through professional aesthetic product suppliers.

Historical commercial documentation refers to European CE certification for selected Rejeunesse products.

However, historical certification does not independently establish current European Medical Device Regulation compliance or authorization of every formulation.

US FDA approval for Rejeunesse Fine, Deep, Shape, or Contour has not been established.

Buyers should verify the responsible legal manufacturer, current product registration, approved intended use, import eligibility, and lawful distribution requirements applicable to their destination country.

This information is intended for professional product identification and commercial evaluation. It does not provide injection instructions, establish patient-specific suitability, or authorize use outside applicable medical device regulations.

Frequently Asked Questions